Vivo Capital’s Astria Therapeutics ATXS Stock Holding History

Vivo Capital’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,552,685	Closed	-$11.3M	–	49
2025 Q3	$11.3M	Hold	1,552,685	–	–	0.91%	29
2025 Q2	$8.32M	Hold	1,552,685	–	–	0.85%	25
2025 Q1	$8.29M	Hold	1,552,685	–	–	1.1%	21
2024 Q4	$13.9M	Hold	1,552,685	–	–	1.56%	13
2024 Q3	$17.1M	Sell	1,552,685 -776,342	-33%	-$8.63M	1.41%	15
2024 Q2	$21.2M	Hold	2,329,027	–	–	1.96%	11
2024 Q1	$32.8M	Sell	2,329,027 -153,700	-6%	-$1.91M	2.58%	10
2023 Q4	$19.1M	Buy	2,482,727 +801,528	+48%	+$4.43M	1.56%	13
2023 Q3	$12.5M	Hold	1,681,199	–	–	1.37%	19
2023 Q2	$14M	Hold	1,681,199	–	–	0.97%	15
2023 Q1	$22.4M	Hold	1,681,199	–	–	1.55%	10
2022 Q4	$25M	Buy	1,681,199 +681,199	+68%	+$7.02M	2.88%	12
2022 Q3	$9.04M	Buy	+1,000,000	New	+$6.7M	1%	27

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital's ATXS Position: Q4 2025 in Review

Vivo Capital sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 1,552,685 shares — an estimated $11.3M sold.

Vivo Capital first reported a position in ATXS in Q3 2022 and held it in 13 quarters. The position peaked at $32.8M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

Vivo Capital reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
Vivo Capital sold 1,552,685 Astria Therapeutics shares in Q4 2025, an estimated $11.3M.
Vivo Capital first reported a position in Astria Therapeutics in Q3 2022 and held it in 13 quarters.
Vivo Capital's Astria Therapeutics position peaked at $32.8M in Q1 2024.
141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Vivo Capital's 13F filing for Q4 2025, filed 13 Feb 2026.